Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Short Communication Volume 3 Issue 5

Short Message to All Healthcare Providers about Coronavirus Infectious Disease-2019 (COVID 19)

Syed Haseeb Raza Naqvi1, Madiha Fatima2 and Han Naung Tun3*

1Department of Cardiac Electrophysiology, National Institute of Cardiovascular Diseases, Karachi, Pakistan
2Post Graduate Resident, Adult Cardiology Department, National Institute of Cardiovascular Diseases, Karachi, Pakistan
3Council of Cardiology Practice, European Society of Cardiology, Sophia Antipolis, France

*Corresponding Author: Han Naung Tun, Council of Cardiology Practice, European Society of Cardiology, Sophia Antipolis, France.

Received: April 06, 2020; Published: April 24, 2020


  Coronaviruses are a group of related viruses, cause respiratory tract infections in human that can be mild as common cold and can be lethal, such as SARS, MERS, and COVID-19. Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified in November 2019 in Wuhan, the capital of China's Hubei province, and has since spread globally, resulting in the ongoing 2019–20 coronavirus pandemic [1].



  1. Zhou P., et al. “A pneumonia outbreak associated with a new coronavirus of probable bat origin”. (2020).
  2. Zou L., et al. “SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients”. The New England Journal of Medicine 382 (2020):1177-1179.
  3. World Health Organization. “Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19)” (2020).
  4. Guan W-j., et al. “Clinical Characteristics of Coronavirus Disease 2019 in China”. The New England Journal of Medicine (2020).
  5. Lauer SA., et al. “The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application”. Annals of Internal Medicine (2020).
  6. Van Doremalen N., et al. “Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1”. The New England Journal of Medicine (2020).
  7. Huang C., et al. “Clinical features of patients infected with 2019 novel coronavirus in Wuhan”. China (2020).
  8. Wilder-Smith A and Freedman DO. Isolation, quarantine, social distancing and community containment: pivotal role for old-style public health measures in the novel coronavirus (2019-nCoV) outbreak (2020).
  9. Infection prevention and control (2019).
  10. CDC - NIOSH-Approved N95 Particulate Filtering Facepiece Respirators - 3M Suppliers List (2020).
  11. Recommendation Regarding the Use of Cloth Face Coverings (2020).
  12. Interim Guidance: Healthcare Professionals 2019-nCoV (2019).
  13. Clinical Specimens: Novel Coronavirus (2019-nCoV) (2020).
  14. Technical guidance (2019).
  15. Sax H., et al. “My five moments for hand hygiene’: a user-centred design approach to understand, train, monitor and report hand hygiene”. Journal of Hospital Infection1 (2007): 9-21.
  16. Infection Control: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (2020).
  17. Welt FGP., et al. “Society of Cardiovascular Angiography. (2020, March 17). Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI (2020).
  18. China National Health Commission. “Diagnosis and treatment of 2019-nCoV pneumonia in China”. In Chinese (2020).
  19. Chen Z., et al. “Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial”. Medicines Rxiv (2020).
  20. Agostini ML., et al. “Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease”. MBio2 (2018): e00221-18.
  21. Cao B., et al. “A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19”. New England Journal of Medicine (2020).
  22. Cai Q., et al. “Experimental treatment with favipiravir for COVID-19: an open-label control study”. Engineering (2020).
  23. Xu X., et al. “Effective treatment of severe COVID-19 patients with Tocilizumab”. China Xiv preprint (2020).
  24. Gautret P., et al. “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial”. International Journal of Antimicrobial Agents (2020): 105949.
  25. , et al. “A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19”. Critical Care 24 (2020): 128.


Citation: Han Naung Tun., et al. “Short Message to All Healthcare Providers about Coronavirus Infectious Disease-2019 (COVID 19)". Acta Scientific Microbiology 3.5 (2020): 119-122.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US